1 completed, 1 recruiting, 1 unknown. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 1, Recruiting 1, Unknown 1 |
Follow Diffuse Large B Cell Lymphoma (DLBCL): new trials by email Literature Review of Diffuse Large B Cell Lymphoma (DLBCL) trials Research Report on Diffuse Large B Cell Lymphoma (DLBCL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel - Large B-cell Lymphoma, Lymphoma, B-Cell | Phase 3 | Recruiting | Lyell Immunopharma, Inc. | 400 | 2026-01-12 | 2026-11-04 |
| A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma Orelabrutinib + R-CHOP, Placebo + R-CHOP - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 3 | Unknown | Beijing InnoCare Pharma Tech Co., Ltd. | 150 | 2022-11-02 | 2024-02-07 |
| R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL Cyclophosphamide, Doxorubicin, Vincristine - Elderly Patients (>65 Years), Diffuse Large B Cell Lymphoma (DLBCL) | Phase 3 | Completed | Fondazione Italiana Linfomi - ETS | 226 | 2003-01-01 | 2010-06-22 |
Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2)
Cyclophosphamide (1) · Doxorubicin (1) · Epirubicin (1) · Granulocyte Colony-Stimulating Factor (1) · Prednisone (1) · Rituximab (1) · Vinblastine (1) · Vincristine (1) · axicabtagene ciloleucel (1) · orelabrutinib (1)
Beijing InnoCare Pharma Tech Co., Ltd. (1) · Fondazione Italiana Linfomi - ETS (1) · Lyell Immunopharma, Inc. (1)
Australia (1) · Canada (1) · China (1) · Italy (1) · United States (1)
Francesco Merli, MD (1) · Marilena Bertini, MD (1) · Weili Zhao (1)